ArticleClinical and experimental medicine2025
The expression of CD109 in B-cell acute lymphoblastic leukemia and its potential as a promising marker for minimal residual disease (MRD) detection.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundCD109 is overexpressed in various tumors, but its role in hematologic malignancies, particularly acute B lymphoblastic leukemia (B-ALL), remains unclear.
methodsCD109 expression was assessed at both mRNA and protein levels in B-ALL patients using real-time quantitative PCR (RQ-PCR) and multiparameter flow cytometry (MFC). The relationship between CD109 expression and clinical and laboratory parameters was examined. The potential of CD109 as a marker for minimal residual disease (MRD) detection was evaluated. Functional studies were conducted in leukemia cell lines.
resultsCD109 mRNA was significantly upregulated in newly diagnosed and relapsed B-ALL patients compared to healthy controls and remission cases. MFC revealed CD109 positivity in 79.0% B-ALL patients, with higher rates in relapsed cases (85.7%) and CD34 + B-ALL patients. CD109 expression was minimal in mature B cells and precursors B cell. CD109 expression remained stable across disease phases including diagnosis, MRD positivity, and relapse. Functional assays demonstrated that CD109-positive Nalm6 cells exhibited significantly increased proliferative and invasive abilities.
conclusionCD109 is upregulated in B-ALL and promotes leukemia cell proliferation and migration. Its consistent expression across disease stages suggests it may be a promising marker for MRD detection, highlighting its clinical significance in leukemia management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.